Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 95
Selected: 0
NCT IDTitle
NCT05572476Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
NCT02421588Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
NCT02684318Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
NCT00147212ET 743 (Yondelis) in Men With Advanced Prostate Cancer
NCT01102426Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
NCT01869400An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer
NCT06050434Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
NCT01970553Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
NCT02451007Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
NCT00786838A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
NCT00359294A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
NCT00072670A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
NCT05153239Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
NCT00884845Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
NCT00050427A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
NCT02163720Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
NCT03427268Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
NCT01735071Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
NCT02249702Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
NCT00877474Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
NCT01299636Study of PM060184 in Patients With Advanced Solid Tumors
NCT01876043Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
NCT02566993Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
NCT05101265Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
NCT02448537A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
NCT05835609PM534 Administered Intravenously to Patients With Advanced Solid Tumors
NCT01273493A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
NCT00113607An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
NCT04383119Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
NCT01846611A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06088290Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT05076396PM14 Administered Intravenously to Patients with Advanced Solid Tumors
NCT04784559Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
NCT02533674Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
NCT05285033RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
NCT02210364Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
NCT00580112An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
NCT00796120An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
NCT02825420Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
NCT03164980QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT01149681Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
NCT03284320Retrospective Study in Sarcoma Patients
NCT02398058Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
NCT00229203A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
NCT03085225Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
NCT01970540Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
NCT02367924Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
NCT04382066Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
NCT01951157A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
NCT01831089Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors